VANGL1 links angiogenesis–stemness programs and tumor microenvironment remodeling: a pan-cancer, multi-omics study with translational validation - Scorecard - MDSpire

VANGL1 links angiogenesis–stemness programs and tumor microenvironment remodeling: a pan-cancer, multi-omics study with translational validation

  • By

  • Wei Zhou

  • Lizhen Wang

  • Mengxing Li

  • Xuan Liu

  • Qing Fang

  • Yang Yu

  • Songjie Zhang

  • Jing Guo

  • Rui Chang

  • Cheng Zhang

  • Tongliang Zhou

  • Yang Liu

  • Xiaoxia Ren

  • Honglin Liu

  • Lihong Liu

  • May 29, 2026

  • 0 min

Share

Clinical Scorecard: VANGL1's Role in Linking Angiogenesis and Stemness Pathways with Tumor Microenvironment Alterations: A Multi-Omics, Pan-Cancer Investigation with Clinical Implications

At a Glance

CategoryDetail
Condition
Key MechanismsVANGL1 is associated with cancer stemness, angiogenesis, and tumor microenvironment remodeling.
Target Population
Care Setting

Key Highlights

  • VANGL1 is upregulated in solid tumors.
  • VANGL1+ malignant cells show enhanced communication with stromal cells through specific pathways.
  • VANGL1 integrates signaling pathways related to cancer stemness and angiogenesis.
  • Knock-down of VANGL1 affects tumor growth and cancer stem cell maintenance.

Guideline-Based Recommendations

Diagnosis

  • Assess VANGL1 expression for prognostic insights.

Management

  • Investigate VANGL1 as a potential therapeutic target.

Monitoring & Follow-up

  • Evaluate VANGL1 expression levels in clinical contexts.

Risks

  • High VANGL1 expression is linked to poor clinical outcomes.

Patient & Prescribing Data

Investigate the role of VANGL1 in tumor microenvironment interactions.

Clinical Best Practices

  • Utilize multi-omics approaches for tumor profiling.
  • Analyze VANGL1 expression in clinical trials.

Related Resources & Content

Original Source(s)

VANGL1 links angiogenesis–stemness programs and tumor microenvironment remodeling: a pan-cancer, multi-omics study with translational validation

  • by Wei Zhou, Lizhen Wang, Mengxing Li, Xuan Liu, Qing Fang, Yang Yu, Songjie Zhang, Jing Guo, Rui Chang, Cheng Zhang, Tongliang Zhou, Yang Liu, Xiaoxia Ren, Honglin Liu, Lihong Liu

  • May 29, 2026

Related Content

Impact of the clonal architecture and probable biallelic inactivation of TET2 mutations in myelodysplastic neoplasms

Case Report: Synovial sarcoma with diffuse myxoid stroma and complete absence of epithelial differentiation in the extremity

Emerging applications of artificial intelligence for risk stratification in head and neck cancer: a scoping review